Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31236186 | 1.00 | ALDH1A1 (0.62) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL31236185 | 1.00 | ALDH1A1 (0.62) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL1284518 | 0.86 | ALDH1A1 (0.64) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL3715354 | 0.84 | ALDH1A1 (0.58) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL28724549 | 0.84 | ALDH1A1 (0.62) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL29572629 | 0.84 | ALDH1A1 (0.62) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL11637696 | 0.82 | CA1 (0.60) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL31198178 | 0.82 | CA1 (0.60) | ALDH1A1CA1CA2CA9HTT | |
| SCHEMBL3474207 | 0.82 | MAPT (0.60) | ALDH1A1HTTNPC1RAB9AHPGD | |
| SCHEMBL31435389 | 0.82 | RAB9A (0.61) | ALDH1A1CA1CA2CA9RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951602-B2 | Mass defect labeling and methods of use thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-05-31 | — | — | US | claimed |
| US-20090061523-A1 | MASS DEFECT LABELING AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-05 | — | — | US | claimed |
| CN-110563593-A | Preparation method of N-methyl-4-bromoaniline | 新岸诺亚（北京）催化科技有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-7951602-B2 | Mass defect labeling and methods of use thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951602-B2 | Mass defect labeling and methods of use thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1732917-B8 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2009-09-09 | — | — | EP | disclosed |
| US-20090061523-A1 | MASS DEFECT LABELING AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-05 | — | — | US | disclosed |
| US-7378240-B2 | Synthesis and evaluation of new cyanine dyes as minor groove of [POLY(dA-dT)]2 binders | LIGHT UP TECHNOLOGIES AB (SE) | 2008-05-27 | — | — | US | disclosed |
| US-7378240-B2 | Synthesis and evaluation of new cyanine dyes as minor groove of [POLY(dA-dT)]2 binders | LIGHT UP TECHNOLOGIES AB (SE) | 2008-05-27 | — | — | US | disclosed |
| US-7378240-B2 | Synthesis and evaluation of new cyanine dyes as minor groove of [POLY(dA-dT)]2 binders | LIGHT UP TECHNOLOGIES AB (SE) | 2008-05-27 | — | — | US | disclosed |
| EP-1732917-A1 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20040132046-A1 | Synthesis and evaluation of new cyanine dyes as minor groove of [POLY (dA-dT)]2 binders | LIGHT UP TECHNOLOGIES AB (SE) | 2004-07-08 | — | — | US | disclosed |
| EP-1390433-A1 | SYNTHESIS AND EVALUATION OF NEW CYANINE DYES AS MINOR GROOVE OF POLY(DA-DT)] 2 BINDERS | Light Up Technologies AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| US-6624153-B2 | Derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure I:for use as anti-tuberculosis | UNIVERSITY OF SCIENCES IN PHILADELPHIA | 2003-09-23 | — | — | US | disclosed |
| US-20030114531-A1 | Halogenated antituberculosis agents | KOBARFARD FARZAD (US) | 2003-06-19 | — | — | US | disclosed |
| WO-2002092019-A2 | HALOGENATED ANTITUBERCULOSIS AGENTS | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | SCIENCES IN PHILADELPHIA, UNIVERSITY OF | 2002-11-21 | — | — | US | disclosed |
| US-6482982-B1 | BACTERICIDES; MYCOBACTERIUM RESISTANCE | UNIVERSITY OF SCIENCES OF PHILADELPHIA | 2002-11-19 | — | — | US | disclosed |
| WO-2002090443-A1 | SYNTHESIS AND EVALUATION OF NEW CYANINE DYES AS MINOR GROOVE OF [POLY(DA-DT)]2 BINDERS | LIGHT UP TECHNOLOGIES AB (SE) | 2002-11-14 | — | — | WO | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090061523-A1 | MASS DEFECT LABELING AND METHODS OF USE THEREOF | PTMS, SPPL2B, NPPA | ALDH1A1 4426/4885CA1 1986/4885CA2 3871/4885 |
| US-20030114531-A1 | Halogenated antituberculosis agents | XDH, TST, QSOX1 | ALDH1A1 277/4885CA1 3534/4885CA2 2193/4885 |
| US-20020173548-A1 | HALOGENATED ANTITUBERCULOSIS AGENTS | XDH, TST, QSOX1 | ALDH1A1 277/4885CA1 3534/4885CA2 2193/4885 |
| US-20040132046-A1 | Synthesis and evaluation of new cyanine dyes as minor groove of [POLY (dA-dT)]2 binders | DRD4, FUT4, DRD1 | ALDH1A1 2246/4885CA1 478/4885CA2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.